Cannabis Insights | PA Legalization?, MD, OR Trackers

11/04/21 07:13AM EDT

Cannabis Insights | PA Legalization?, MD, OR Trackers - dash

PA Legalization?

Voters in Philadelphia sent a clear message to lawmakers as they broadly approved a referendum on marijuana legalization. A growing number of state senators are stepping up to push some reform across Pennsylvania. Results from Tuesday's election show the proposal receiving a 73% approval rate. With Philadelphia already decriminalizing cannabis, the city aimed to enact broader reform statewide using this referendum to motivate the legislature further to move ahead with legalization. Although there has already been a broad bill introduced, the state congress is primarily GOP-controlled and has resisted calls from top officials and the public so far. Jushi and Terrascend both have the greatest exposure to Pennsylvania, with 59% and 35% of their assets concentrated in the state respectively. Along with Green Thumb and Verano, these companies are positioned to benefit the most from legalization in the state. 

Oregon Tracker

For the third month in a row, sales in Oregon were down to $93.6 Million, which is down 2% sequentially and 5.5% YoY. After an initial spike due to covid, sales have been relatively flat in the state. The annual run rate for Oregon is $1.16 Billion. We continue to expect mature states to have flat to decelerating sales for the foreseeable future. 

Cannabis Insights | PA Legalization?, MD, OR Trackers - or

Maryland Tracker

Sales in the state saw a rebound this past quarter jumping 3.8% sequentially and 7% YoY. Sales came in at about $46 Million for the month. Medical states continue to see better performance in October compared to recreational markets. The annual run rate for the state is $543 Million. 

Cannabis Insights | PA Legalization?, MD, OR Trackers - maryland

© 2024 Hedgeye Risk Management, LLC. The information contained herein is the property of Hedgeye, which reserves all rights thereto. Redistribution of any part of this information is prohibited without the express written consent of Hedgeye. Hedgeye is not responsible for any errors in or omissions to this information, or for any consequences that may result from the use of this information.